Brokerages predict that Uniqure NV (NASDAQ:QURE) will post earnings of ($0.66) per share for the current quarter, according to Zacks. Four analysts have made estimates for Uniqure’s earnings, with estimates ranging from ($0.70) to ($0.61). Uniqure reported earnings of ($0.91) per share in the same quarter last year, which would indicate a positive year-over-year growth rate of 27.5%. The firm is expected to report its next quarterly earnings report on Wednesday, March 13th.

On average, analysts expect that Uniqure will report full-year earnings of ($2.57) per share for the current year, with EPS estimates ranging from ($3.20) to ($2.36). For the next fiscal year, analysts expect that the firm will report earnings of ($2.83) per share, with EPS estimates ranging from ($3.50) to ($2.35). Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Uniqure.

Uniqure (NASDAQ:QURE) last announced its quarterly earnings results on Tuesday, November 6th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.62) by $0.03. Uniqure had a negative net margin of 725.04% and a negative return on equity of 58.49%. The firm had revenue of $3.15 million during the quarter, compared to the consensus estimate of $3.37 million.

Several equities analysts recently issued reports on QURE shares. Zacks Investment Research raised shares of Uniqure from a “hold” rating to a “buy” rating and set a $33.00 price target for the company in a report on Wednesday, October 10th. Cowen reaffirmed a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. HC Wainwright set a $48.00 target price on shares of Uniqure and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Chardan Capital boosted their target price on shares of Uniqure from $50.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Finally, BidaskClub raised shares of Uniqure from a “sell” rating to a “hold” rating in a research note on Friday, October 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $55.67.

Shares of QURE stock opened at $30.75 on Tuesday. Uniqure has a 12-month low of $14.99 and a 12-month high of $43.23. The stock has a market cap of $1.10 billion, a P/E ratio of -10.46 and a beta of 0.81. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of 0.05.

In other Uniqure news, Director Philip Astley-Sparke sold 5,000 shares of the business’s stock in a transaction dated Monday, December 3rd. The shares were sold at an average price of $30.39, for a total value of $151,950.00. Following the completion of the transaction, the director now directly owns 23,252 shares of the company’s stock, valued at $706,628.28. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 1.56% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of QURE. OppenheimerFunds Inc. bought a new stake in shares of Uniqure during the second quarter worth approximately $63,553,000. Redmile Group LLC bought a new stake in shares of Uniqure during the second quarter worth approximately $61,402,000. FMR LLC raised its stake in shares of Uniqure by 16.6% during the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock worth $139,659,000 after buying an additional 526,283 shares during the last quarter. Federated Investors Inc. PA raised its stake in shares of Uniqure by 18.9% during the second quarter. Federated Investors Inc. PA now owns 1,091,280 shares of the biotechnology company’s stock worth $41,250,000 after buying an additional 173,281 shares during the last quarter. Finally, Baker BROS. Advisors LP raised its stake in shares of Uniqure by 21.0% during the second quarter. Baker BROS. Advisors LP now owns 605,000 shares of the biotechnology company’s stock worth $22,869,000 after buying an additional 105,000 shares during the last quarter. 60.62% of the stock is owned by institutional investors and hedge funds.

Uniqure Company Profile

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Featured Story: Put Option

Get a free copy of the Zacks research report on Uniqure (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.